HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study.

Abstract
In this pilot study we investigated 10 women suffering from primary fibromyalgia. All patients received 5 mg of tropisetron in the evening, for a period of 4 weeks. Clinical disease variables included the measurement of a pain score, fatigue, sleep disturbances and measurement of the number of tender points. Five of our patients (50%) showed a statistical clinical improvement of all the above parameters starting after the first week of treatment. Two patients did not respond to the therapy and three discontinued the study because of side-effects. We conclude that administration of tropisetron in fibromyalgia patients could be useful in the management of this difficult and incurable syndrome.
AuthorsI A Papadopoulos, P E Georgiou, P P Katsimbri, A A Drosos
JournalClinical rheumatology (Clin Rheumatol) Vol. 19 Issue 1 Pg. 6-8 ( 2000) ISSN: 0770-3198 [Print] Germany
PMID10752491 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Indoles
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT3
  • Serotonin Antagonists
  • Tropisetron
Topics
  • Adult
  • Female
  • Fibromyalgia (drug therapy, metabolism)
  • Humans
  • Indoles (therapeutic use)
  • Middle Aged
  • Pain Measurement
  • Pilot Projects
  • Receptors, Serotonin (drug effects)
  • Receptors, Serotonin, 5-HT3
  • Serotonin Antagonists (therapeutic use)
  • Treatment Outcome
  • Tropisetron

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: